Connect Biopharma Files 6-K with Mid-Year Financials

TL;DR

Connect Biopharma dropped its 6-K with H1 2024 financials - check the balance sheet.

AI Summary

Connect Biopharma Holdings Ltd filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the six months ended June 30, 2024, and comparative periods. Specific financial figures such as issued capital, share premium, and treasury shares are detailed for various dates including December 31, 2022, and June 30, 2023.

Why It Matters

This filing provides investors with updated financial statements, offering insights into the company's financial health and performance for the first half of 2024.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) that provides updated financial information and does not introduce new material risks.

Key Numbers

• 2024-06-30 — Reporting Period End Date (Indicates the latest financial data presented in the filing.)
• 2024-01-01 — Reporting Period Start Date (Marks the beginning of the period for which financial data is reported.)

Key Players & Entities

• Connect Biopharma Holdings Ltd (company) — Filer of the 6-K report
• June 30, 2024 (date) — End of the reporting period
• December 31, 2022 (date) — Comparative financial reporting date
• June 30, 2023 (date) — Comparative financial reporting date

FAQ

Filing Documents

• cntb-20240630.htm (6-K) — 929KB
• cntbh12024earningsreleasef.htm (EX-99.1) — 61KB
• 0001835268-24-000023.txt ( ) — 5950KB
• cntb-20240630.xsd (EX-101.SCH) — 73KB
• cntb-20240630_cal.xml (EX-101.CAL) — 88KB
• cntb-20240630_def.xml (EX-101.DEF) — 176KB
• cntb-20240630_lab.xml (EX-101.LAB) — 534KB
• cntb-20240630_pre.xml (EX-101.PRE) — 382KB
• cntb-20240630_htm.xml (XML) — 954KB

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 26 EXHIBITS 33

SIGNATURES

SIGNATURES 34 INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K On September 5, 2024, Connect Biopharma Holdings Limited (the "Company") reported the Company's financial results for the six-month period ended June 30, 2024. This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration No. 333-264340) and Form S-8 (Registration Nos. 333-254524 and 333-266006) of the Company and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. Notwithstanding the foregoing, the information set forth in the attached Exhibit 99.1 shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing. The furnishing of the attached exhibits is not an admission as to the materiality of any information therein. The information contained in the exhibits may comprise summary information that is intended to be considered in the context of more complete information included in the Company's filings with the Securities and Exchange Commission (the "SEC") and other public announcements that the Company has made and may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing or furnishing of other reports or documents with the SEC, through press releases, by updating its website or through other public disclosures. All references in this annual report to "$" and "US$" mean U.S. dollars and all references to "RMB" mean renminbi. i CONNECT BIOPHARMA HOLDINGS LIMITED INDEX TO THE UNAUDITED IN

View Full Filing

View this 6-K filing on SEC EDGAR